Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading
Merger News Boosts Pieris (PIRS) Stock In Pre-Market Trading
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) shares surged significantly on US stock charts after the announcement of a formal merger agreement. Pre-market activity showed that PIRS stock had increased impressively by 69.27%, to $13.44 per share.
Pieris Pharmaceuticals公司 (NASDAQ: PIRS) 的股票在美國股票圖表上大幅上漲，原因是正式公佈了一項合併協議。盤前交易顯示，PIRS的股票印象中上漲了69.27%，至每股 13.44美元。
Table of Contents
目錄
- The Merger Agreement
- Strategic Focus and Future Prospects
- Prospective Development
- 合併協議
- 戰略重點和未來前景
- 前景發展
The Merger Agreement
合併協議
Pieris Pharmaceuticals (PIRS) has entered into a definitive merger agreement with Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for rare genetic skin disorders lacking FDA-approved therapies.
Pieris Pharmaceuticals (PIRS)已與Palvella Therapeutics，Inc.達成明確的合併協議，後者是一家專門開發罕見遺傳性皮膚疾病創新治療方案的臨床生物製藥公司，這些疾病缺乏FDA認可的治療方案。
In order to cancel Palvella's capital stock and make Palvella a wholly-owned subsidiary of Pieris, this strategic merger will comprise an all-stock transaction in which Pieris would issue shares of its common stock to pre-merger Palvella investors.
爲了取消Palvella的股本並使Palvella成爲Pieris的全資子公司，這項戰略性合併將包括一項全股票交易，其中Pieris將向合併前的Palvella股東發行其普通股。
Strategic Focus and Future Prospects
戰略重點和未來前景
The combined entity will concentrate on advancing and commercializing Palvella's leading clinical product candidate, QTORIN 3.9% rapamycin anhydrous gel. This therapeutic gel is designed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and other severe skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.
合併後的聯合實體將致力於推進並商業化Palvella的領先臨床產品候選者QTORIN 3.9%無水拉帕黴素凝膠。該治療凝膠旨在治療由哺乳動物靶向拉帕黴素(mTOR)通路過度活化驅動的微囊性淋巴管畸形、皮膚靜脈畸形和其他嚴重皮膚疾病。
Following the merger, the new business will continue to operate under the name Palvella Therapeutics, Inc.; it will have its headquarters in Wayne, Pennsylvania, and it plans to list on The Nasdaq Capital Market.
合併後，新公司將繼續以Palvella Therapeutics，Inc.的名義運營；其總部位於賓夕法尼亞州韋恩，並計劃在納斯達克資本市場上市。
Prospective Development
前景發展
This merger underscores Pieris Pharmaceuticals' commitment to delivering value to its shareholders by preserving the future potential milestone and royalty streams from its partnered immuno-oncology bispecifics franchise through Contingent Value Rights (CVRs) for legacy Pieris stockholders.
此次合併凸顯了Pieris Pharmaceuticals保留其合作免疫腫瘤雙特異性分子系列的未來潛在里程碑和版稅流的承諾，通過爲傳統PIERIS股東提供有條件的價值權(CVRs)。
Moreover, it offers the potential for significant growth within a promising, late-stage rare disease company. With anticipated funding and a seasoned management team, the merged company is poised to advance a Phase 3 clinical program, benefiting from the FDA's Breakthrough, Fast Track, and Orphan Drug Therapy Designations.
此外，它提供了在一個有前途的晚期罕見疾病公司內實現顯著增長的潛力。隨着預期的資金和經驗豐富的管理團隊，合併後的公司有望推進第III期臨床計劃，受益於FDA的突破性、快速通道和孤兒藥物治療指定。
Post-merger, pre-merger Pieris stockholders are projected to hold approximately 18% of the combined company, while pre-merger Palvella stockholders are expected to own around 82%, prior to the issuance of shares under concurrent private financing.
合併後，合併前的Pieris股東預計將持有約18%的合併公司股份，而合併前的Palvella股東預計將持有約82%的股份，在同時進行的私募融資下發行股份之前。
譯文內容由第三人軟體翻譯。